Cancers of the Head and Neck Completed Phase 3 Trials for Zalutumumab (DB12202)

Also known as: Cancer of the Head and Neck

IndicationStatusPhase
DBCOND0065283 (Cancers of the Head and Neck)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00496652DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCCTreatment